Metabolix, Inc., a bioscience company, focuses on delivering sustainable solutions to the plastics and chemicals industries. The company’s targeted markets of plastics and chemicals offer substantial opportunity for innovation and value creation. It focuses on a family of biopolymers found in nature called polyhydroxyalkanoates (PHAs), which occur naturally in living organisms and are chemically similar to polyesters. The company has core capabilities in microbial genetics, fermentation process engineering, chemical engineering, polymer science, plant genetics and botanical science. PHA Biopolymers Platform The company holds exclusive rights to the Metabolix technology and intellectual property used in the joint venture. It acquired all of Telles's product inventory and compounding raw materials, all product certifications and all product trademarks, including Mirel and Mvera, and it retained all co-funded pilot plant equipment in locations outside of the Archer Daniels Midland Company commercial manufacturing facility in Clinton, Iowa. Biobased Industrial Chemicals Platform The company is developing C4 and C3 chemicals from biobased sources, as opposed to the fossil fuels that are used to produce most industrial chemicals. The company’s process for creating biobased industrial C4 and C3 chemicals involves engineering metabolic pathways into microbes that, in a fermentation process, produce specific PHA structures that serve as precursors for these chemicals. Crops Platform The company is harnessing the renewable nature of plants to make renewable chemicals and bioenergy from crops. The company is working to create proprietary systems to produce PHB in high concentration in the leaves of biomass crops or in the seeds of oilseed crops for these multiple applications. Strategy Key elements of the company’s strategy include creating a product portfolio of proprietary biopolymers and biopolymer formulations; establishing a supply chain for PHA biopolymers; sourcing complementary biopolymers; managing existing inventory; market positioning and technical support; continuing microbial research and process development; extending its technology to sustainable production of biobased chemicals and intermediates; advancing plant crop research; partnering its programs; and furthering its leading and competitive intellectual property position. Intellectual Property The company owns approximately 380 issued patents and approximately 140 patent applications worldwide, and it has licensed from third parties approximately 25 issued patents and patent applications worldwide. In 2013, the company filed approximately 50 patent applications worldwide, including applications for 5 new inventions covering biodegradable films, PHAs as additives for polymer applications, and the use of PHA-containing biomass to produce biobased industrial chemicals, as well as alternate feedstocks for producing novel biobased chemicals from genetically engineered microbes. The company were also granted or allowed 15 patent applications in 2013, 7 in the United States of America and 8 internationally. The company’s extensive patent portfolio covers, among other things, the fundamental biotechnology needed to produce Mirel biopolymers and a range of biobased chemicals, as well as biopolymer compositions, processes and derived products. The licensed patents and patent applications include patents covering its core technology that are owned by Massachusetts Institute of Technology and exclusively licensed to the company. The company’s intellectual property portfolio includes patents directed to compositions of polymers, genes, vectors, expression systems in plants and microbes, polymer compositions of matter and formulations, devices, coatings and films, as well as methods of manufacture and use. The terms of such patents are set to expire at various times between 2014 and 2032. The company’s registered U.S. trademarks include Metabolix, the Metabolix four-leaf design, Telles, Mirel, the Mirel heart-leaf design, Mvera and Biopol. These marks and certain other trademarks have also been registered in selected foreign countries. Research and Development Expenses During the year ended December 31, 2013, the company spent approximately $19.1 million on company-sponsored research and development activities. Competition The company competes with Genomatica, Myriant, BioAmber, OPX/Dow, Cargill/Novozymes, and Novomer. History The company was founded in 1992. It was incorporated in Massachusetts in 1992 under the name Metabolix, Inc. In 1998, the company reincorporated in Delaware.
metabolix inc (MBLX:NASDAQ GM)
21 Erie Street
Cambridge, MA 02139
|No competitor information is available for MBLX.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact METABOLIX INC, please visit www.metabolix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.